Compare IDEXX Laboratories, Inc. (IDXX) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Infosys Limited — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Infosys Limited trades at $11.28 (market cap $46.65B). The key difference: IDEXX Laboratories, Inc. and Infosys Limited are close in size by market cap, and Infosys Limited pays a 4.63% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | INFY | |
|---|---|---|
Market Cap | $44.48B | $46.65B |
Sector | Health | Technology |
52-Week High | $766.68 | $20.22 |
52-Week Low | $520.87 | $10.49 |
Enterprise Value | $45.38B | $43.87B |
Dividend Yield | — | 4.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
INFY trades at $11.31, down 1.57% on the day, with a bullish technical signal despite bearish moving averages. The stock shows strong profitability with a 16.44% net income margin and 31.57% ROE, supported by recent earnings beats. Recent news highlights AI collaborations with firms like Sentara and GlobalFoundries, positioning the company for growth in enterprise AI services.
The outlook is cautiously optimistic with a consensus price target of $12.28, implying 8.6% upside. Risks include competitive pressures in IT services and potential volatility from sector-wide demand concerns, as seen with Accenture's recent outlook. Analyst sentiment is mixed, with 37.5% buy ratings but a majority hold stance, reflecting balanced near-term expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
